PNC
59
-2
SRE
42
-3
AKAM
35
-5
NWSA
71
-5
MU
48
-4
TXN
42
-6
HES
68
-2
PLD
28
-4
GS
48
-2
NRG
57
-2
AAL
20
-3
DD
33
-4
ADT
66
-5
ECL
40
-5
HPQ
37
-12
LUV
52
-4
NUE
36
-5
NWS
64
-5
PH
60
-7
URI
42
-3
PNC
59
-2
SRE
42
-3
AKAM
35
-5
NWSA
71
-5
MU
48
-4
TXN
42
-6
HES
68
-2
PLD
28
-4
GS
48
-2
NRG
57
-2
AAL
20
-3
DD
33
-4
ADT
66
-5
ECL
40
-5
HPQ
37
-12
LUV
52
-4
NUE
36
-5
NWS
64
-5
PH
60
-7
URI
42
-3
Financhill
Back

Royalty Pharma PLC 10K Form

Sell
28

RPRX
Royalty Pharma PLC

Last Price:
$31.38
Seasonality Move:
-2.74%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-09 10Q RPRX/Royalty Pharma PLC Quarterly
2023-11-08 10Q RPRX/Royalty Pharma PLC Quarterly
2023-08-08 10Q RPRX/Royalty Pharma PLC Quarterly
2023-05-09 10Q RPRX/Royalty Pharma PLC Quarterly
2022-11-08 10Q RPRX/Royalty Pharma PLC Quarterly
2022-08-04 10Q RPRX/Royalty Pharma PLC Quarterly

Receive RPRX News And Ratings

See the #1 stock for the next 7 days that we like better than RPRX

RPRX Financial Statistics

Sales & Book Value

Annual Sales: $2.3B
Cash Flow: $742.5M
Price / Cash Flow: 6.73
Annual Sales: $15.58
Price / Book: 1.96

Profitability

EPS (TTM): 1.80310
Net Income (TTM): $859M
Gross Margin: $0
Return on Equity: 8.54%
Return on Assets: 4.97%

Royalty Pharma PLC Earnings Forecast

Key Royalty Pharma PLC Financial Ratios

  • The Gross Profit Margin over the past 11 years for RPRX is 0.00%.
  • The Selling, General & Administrative Expenses for RPRX have been equal to 10.46% of Gross Profit Margin.
  • The Research & Development expenses have been 0.09% of Revenue.
  • The Interest Expense is 26.25% of Operating Income.
  • The Net Earning history of RPRX is 37.95% of Total Revenues.
  • Per Share Earnings over the last 20 years have been positive in 10 years.

Royalty Pharma PLC Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: RPRX
CUSIP: G7709Q
Website: royaltypharma.com

Debt

Debt-to-Equity Ratio: 1.1
Current Ratio: 1.44
Quick Ratio: 1.43

Price-to-Earnings

Trailing P/E Ratio: 16.42
Forward P/E Ratio: 6.29

RPRX Technical Analysis vs Fundamental Analysis

Sell
28
Royalty Pharma PLC (RPRX) is a Sell

Is Royalty Pharma PLC a Buy or a Sell?